-
Product Insights
Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain, and shortness of breath. Causes include cardiomyopathy, ischemic heart disease, and heart failure. Risk factors include age, family history, and medical history. Treatment includes antiarrhythmic medication. The Ventricular Tachycardia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action...
-
Sector Analysis
Angina Pectoris - Global Drug Forecast and Market Analysis to 2028
Angina pectoris, or angina for short, refers to chest pain or discomfort caused by insufficient blood supply to the heart muscle, known as myocardial ischemia, when myocardial oxygen demand exceeds oxygen supply. In chronic forms of angina, ischemia of the myocardium can be caused by fixed epicardial coronary artery atherosclerotic obstruction, by microvascular dysfunction (MVD) involving the smaller vessels of the heart, or coronary artery spasm. This report focuses on the following forms of angina: stable angina (atherosclerotic obstruction), microvascular,...
-
Sector Analysis
OpportunityAnalyzer: Pulmonary Arterial Hypertension – Opportunity Analysis and Forecasts to 2026
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary arterial pressure (>25mmHg compared with normal levels of around 14mmHg). This increased pressure is caused by pulmonary arterial obstruction due to endothelial dysfunction and vascular remodeling, and leads to...
-
Sector Analysis
OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,501 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan),...
-
Sector Analysis
OpportunityAnalyzer: Pulmonary Arterial Hypertension – Opportunity Analysis and Forecast to 2024
GlobalData estimates the 2014 sales for pulmonary arterial hypertension (PAH) at approximately $3.45 billion across the 7MM covered in this report, which include the US, 5EU and Japan. The market will grow moderately at a CAGR of 3.20% during the 10-year forecast period, generating sales of approximately $4.75 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 3.70% and generating around 75% of global sales in...
-
Sector Analysis
Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Cardiomyopathies market size was approximately $1.6 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 12% during the forecast period. The US is the most significant contributor to that revenue.
-
Sector Analysis
PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2025
GlobalData estimates sales of HF therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of $11.5B by 2025. The 7MM chronic HF market size in 2015 was $3.1B, and is expected to increase to $10.1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total...
-
Sector Analysis
PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control. All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important...
-
Sector Analysis
PharmaPoint: Acute Coronary Syndrome – Global Drug Forecast and Market Analysis to 2025
Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable...
-
Sector Analysis
PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2025
Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual's deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.